@myueg.bsky.social🧠#Ustekinumab offers a safety advantage after #vedolizumab failure in #UC
🔸 Similar remission rates with infliximab, anti-TNF SC & ustekinumab
🔸 Fewer adverse events and treatment discontinuations with ustekinumab
Read the full article in UEG Journal:
👉 https://bit.ly/4gPXeKa
@nikolospharma.bsky.social